Date: 2017-01-12
Type of information: R&D agreement
Compound: small molecules against viral infectious diseases
Company: Evotec (Germany) Haplogen (Austria)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism:
Disease: viral infectious diseases
Details: * On November 15, 2012, Haplogen GmbH and Evotec AG have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Under the agreement, Haplogen and Evotec will co-develop drugs against a human protein that is essential for pathogenic viruses to infect their host cell. This protein was discovered by Haplogen’s powerful proprietary technology to identify host factors for infectious human pathogens. Evotec will further develop Haplogen’s lead compounds and apply its drug discovery platform to find additional small molecule inhibitors. Terms of the partnership were not disclosed.
Financial terms:
Latest news: * On January 12, 2017, Haplogen announced a research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec. The article published in Nature describes the work performed at Dr Brummelkamp’s laboratory at the Netherlands Cancer Institute (“PLA2G16 represents a switch between entry and clearance of Picornaviridae”, Jacqueline Staring, Eleonore von Castelmur, Vincent A Blomen, Lisa G. van den Hengel, Markus Brockmann, Jim
Baggen, Hendrik Jan Thibaut, Joppe Nieuwenhuis, Hans Janssen, Frank van Kuppeveld, Anastassis
Perrakis, Jan E. Carette & Thijn R. Brummelkamp ; Nature (2017).
PLA2G16 represents a first-in-class drug target for a broad range of picornaviruses. Haplogen holds the exclusive rights to use PLA2G16 against viral infections. In this partnership with Evotec, it has developed novel inhibitor compounds, which it anticipates to enter pre clinical development in the course of 2017.
